ABSTRACT
Aim of the study was to analyze the validity of pharmacoepidemiological purpose and structure of lipid-lowering therapy (LLT) in patients with hypertension and dyslipidemia in clinical practice. Demonstrated commitment to the basic principles of medical verification of cardiovascular events with an adequate definition of risk SCORE scale for patients with high and very high risk. However, the lack of definition of fractions of cholesterol is not allowed to make the right decision on the appointment of GLT for a number of patients with low and moderate risk. The advantage in the appointment of atorvastatin used (32.3%), simvastatin (27.8%) and rosuvastatin (20.9%), and from the antihypertensive subgroups - angiotensin converting enzyme inhibitors, -blockers, calcium antagonists, sartan. Revealed insufficient control of blood lipid in the dynamics on the background of LLT, low activity of doctors in the statin dose titration and use of combined LLT (6.9%) in order to achieve target levels of atherogenic key biochemical parameters. Taking into account the literature data on the most effective and priorities destination rosuvastatin and its high safety in clinical situations of forced polypharmacy we conducted pharmacoeconomic comparison of rosuvastatin several manufacturers of direct cost. Established a price advantage of rosuvastatin (tevastor) with respect to both the original drug, and to a number specified in the prescribing of generics. No fixed assignment LLT is testimony not revealed irrational combinations of drugs with contraindications recommendations, including the appointment of antihypertensive drugs. CONCLUSION: Further work is needed to evaluate pharmacoeconomic indicators LLT, to raise awareness of physicians to enhance quality control of medical assistance and measures to reduce the risk of complications in patients with cardiovascular disease of atherosclerotic origin.
